{"filings":[{"id":442396,"accession_number":"0001628280-26-035068","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-05-14T20:03:27+00:00","items":["5.07"],"status":"ready","headline":"TriSalus annual meeting elects two directors, ratifies auditor, approves say-on-pay frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mary Szela and Gary Gordon elected to three-year director terms with ~92% for votes.","Grant Thornton LLP ratified as independent auditor for fiscal 2026.","Advisory vote on exec compensation approved; board adopts three-year frequency for future votes.","Turnout: 67.9% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40121,"accession_number":"0001628280-26-034082","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-05-12T20:03:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.","Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.","Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.","2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.","Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":8899000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95894,"accession_number":"0001628280-26-028425","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences Chief of Clinical Operations Jodi Devlin to retire October 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jodi Devlin notified Company on April 24, 2026 of retirement as Chief of Clinical Operations.","Retirement effective October 1, 2026; Company expresses gratitude for her contributions.","Previously announced Dr. Richard Marshall as new Chief Medical Officer effective June 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95893,"accession_number":"0001628280-26-023991","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $525,000; sign-on bonus of $250,000.","Eligible for annual bonus up to 50% of base salary based on board-determined goals.","Board will recommend granting 120,000 stock options and 60,000 restricted stock units.","Marshall, previously Medical Director since Jan 2025, will lead medical strategy and clinical development.","Appointment strengthens leadership as TriSalus advances its PEDD platform for solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109303,"accession_number":"0001628280-26-015155","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.","Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.","Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.","Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.","Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109302,"accession_number":"0001493152-26-007598","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"TriSalus prices $40M public offering of 9.76M shares at $4.10/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).","Underwriters granted 30-day option to purchase up to 1,463,415 additional shares (15% of offering).","Offering expected to close February 23, 2026; Lake Street Capital Markets sole book-runner.","Net proceeds estimated at ~$42.64M if over-allotment fully exercised.","Proceeds for general corporate purposes including working capital and G&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109301,"accession_number":"0001628280-26-006219","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences appoints Michael Stansky to board, replacing Dr. Desai","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Arjun \"JJ\" Desai resigned from the board on February 3, 2026; no disagreement with the company.","Michael P. Stansky appointed to the board effective February 4, 2026.","Stansky brings 40 years of investment management and healthcare experience; former Managing Director at Tudor Investment Corp.","He will serve on the Audit, Compensation, and Science and Technology Committees.","Stansky currently serves on boards of Insightec and Momentis Surgical; past boards include Mako Surgical and Transmedics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109300,"accession_number":"0001628280-26-001743","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.","Revenue growth exceeded prior guidance of 50% annual growth for 2025.","Initial 2026 revenue guidance set at $60M to $62M.","Year-end cash approx $20.4M, down $2.3M from start of Q4 reflecting investment in growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":45151000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125792,"accession_number":"0001628280-25-052008","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q3 revenue $11.6M (+57% YoY); net loss $41.3M on preferred conversion; reaffirms 50% FY growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.","Gross margin 84% vs 86% prior year; operating loss $9.0M vs $8.7M.","Net loss attributable to common $41.3M ($0.96 EPS) due to $30.5M preferred conversion charge.","Adjusted EBITDA loss improved to $5.4M from $7.2M; cash $22.7M with runway to positive adj. EBITDA.","Reaffirmed FY2025 revenue growth of at least 50%; initiated GAE trial for knee OA; published thyroid embolization data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":31946000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125791,"accession_number":"0001628280-25-043440","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus director Sean Murphy resigns from Board and Science Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sean Murphy resigned from the Board and the Science and Technology Committee effective September 30, 2025.","Resignation is not due to any disagreement with the Company's operations, policies, or practices.","Murphy served as a director and on the Science and Technology Committee of TriSalus Life Sciences.","The Company's stock trades on Nasdaq under the symbol TLSI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142523,"accession_number":"0001826667-25-000129","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences raises CFO base salary to $550K, grants performance-based stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO David Patience's annual base salary increased from $450K to $550K, effective immediately.","Compensation Committee approved stock options for 249,899 shares at $5.11 per share.","Options vest upon company achieving ≥$75M revenue in any 12 consecutive months by Dec 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142522,"accession_number":"0001826667-25-000115","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.","Operating loss improved to $7.3M from $8.2M; net loss $9.0M ($0.27 diluted EPS loss).","Reaffirmed FY2025 revenue growth at least 50%; cash $26.5M, runway to positive adj. EBITDA H1 2026.","Launched TriNav FLX for tortuous vessels; early sales exceeded internal projections.","Simplified capital structure via exchange of Series A Preferred stock completed post-quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":20380000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142521,"accession_number":"0001826667-25-000103","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"TriSalus completes Preferred Stock exchange; 98.82% tendered at 3.3 common shares each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 98.82% of outstanding Series A Convertible Preferred Stock (3,551,502 shares) validly tendered in exchange offer.","Each preferred share exchanged for 3.3 shares of common stock, based on a $4.00 per common share conversion price.","Amendment to Certificate of Designations filed July 24, 2025, enabling mandatory conversion of remaining preferred shares.","Settlement of all validly tendered shares expected on or before August 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160565,"accession_number":"0001826667-25-000077","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TriSalus launches exchange offer for Series A Preferred, up to 11.9M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers up to 11,860,206 common shares in exchange for each share of Series A Convertible Preferred at $4.00 per share based on liquidation preference plus accrued dividends through Aug 10, 2027.","Consent solicitation seeks amendment to automatically convert remaining Preferred after offer closes at a ratio 11.3% lower than exchange offer.","Holders representing ~55% of outstanding Preferred have agreed to tender and consent via Tender and Support Agreements.","Expiration date: 12:01 a.m. ET on July 23, 2025; shares can be withdrawn anytime before.","3,594,002 Preferred shares outstanding as of June 13, 2025; Preferred stock not publicly traded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160564,"accession_number":"0001826667-25-000074","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TriSalus shareholders elect Wahlström and Matlin to board, ratify Grant Thornton","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mats Wahlström and David J. Matlin elected to three-year terms with 20,002,109 and 20,005,151 votes for, respectively; 5,978,753 broker non-votes each.","Ratification of Grant Thornton as independent auditor for 2025: 26,445,528 for, 36,277 against, 994 abstain.","26,482,799 of 36,180,828 outstanding shares (73.2%) represented at the June 12, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160563,"accession_number":"0001826667-25-000071","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences appoints David Patience as CFO; James Young resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.","David Patience appointed CFO effective July 1, 2025; base salary $450,000, sign-on bonus $159,000, eligible for 50% annual bonus and 1% stock option grant.","Dan Giordano, VP of Finance, serves as acting CFO during transition; Young remains available for orderly handover.","Patience previously CFO at Accelerate Diagnostics; also held roles at Morgan Stanley, Continental Advisors, and Nuveen Investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160562,"accession_number":"0001826667-25-000049","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q1 rev $9.2M (+42% YoY); revises 2025 guidance: 50% growth, no adj. EBITDA positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $9.2M, up 42% YoY and 11% sequential; gross margin 84% vs 85%.","Net loss available to common $10.4M ($0.39 diluted loss per share) vs $13.2M ($0.60) prior year.","Adjusted EBITDA loss narrowed to $5.5M from $10.4M; cash $13.0M at Mar 31, then raised $22M via private placement.","2025 guidance: confirms 50% rev growth; no longer expects adj. EBITDA or cash flow positive in 2025.","Agreement with 55% of preferred shareholders to simplify capital structure; preferred conversion by mid-July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":9167000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160561,"accession_number":"0001104659-25-041862","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"TriSalus announces $22M private placement, Q1 revenue up 42% to $9.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Private placement of 5.5M shares at $4.00/share raises ~$22M gross; led by Nantahala Capital, Broadfin Holdings. Expected close May 2, 2025.","Preliminary Q1 2025 revenue ~$9.2M (solely from TriNav Infusion System), +42% YoY.","Exchange offer for Series A Preferred Stock: each share exchanged for common at formula based on $10.00 liquidation preference plus accrued dividends through Aug 2027 divided by $4.00.","Special meeting to vote on amendment allowing company to call Preferred Stock for conversion and eliminate July 2027 conversion price reset."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":9167000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160560,"accession_number":"0001826667-25-000036","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus director George Kelly Martin resigns effective April 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin resigned from Board, Audit Committee, and Compensation Committee effective immediately.","Resignation not due to any disagreement with Company on operations, policies, or practices.","Company expressed gratitude for Martin's service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160559,"accession_number":"0001826667-25-000033","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus board member Liselotte Hyveled resigns; no disagreement cited","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Liselotte Hyveled resigned from the Board, Nominating and Corporate Governance Committee, and Science and Technology Committee, effective April 16, 2025.","Resignation not due to any disagreement with the Company’s operations, policies, or practices.","No replacement director named; Board composition reduced by one member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178809,"accession_number":"0001826667-25-000024","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.","Filing a Form 12b-25 for late 10-K due to errors in stock-based compensation and R&D expense timing.","Reaffirms 2025 guidance: >50% revenue growth, >20% OpEx reduction, positive EBITDA, positive cash flow H2 2025.","Cash $8.5M at Dec 31, plus $15M available under $50M OrbiMed credit facility.","Launched TriNav LV and TriGuide catheters; DELIVER program expanding addressable market to >$1B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178808,"accession_number":"0001826667-25-000021","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences officer Sean Murphy to step down Feb 28, remains on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sean Murphy notified intent to step down as officer and employee effective February 28, 2025.","Mr. Murphy will continue to serve as a member of the Board of Directors.","No replacement officer named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178807,"accession_number":"0001826667-25-000018","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.03","3.02"],"status":"ready","headline":"TriSalus draws $10M under senior secured credit facility; issues warrants for 91,263 shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed Second Tranche of $50M credit facility, receiving $10M on Feb 18, 2025.","Loan maturity date is April 30, 2029.","Issued warrants to OrbiMed to purchase 91,263 shares at $5.4787 per share.","Warrants have a 7-year term and contain customary share/price adjustment provisions.","Third Tranche of up to $15M remains available until Dec 31, 2025 subject to revenue conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178806,"accession_number":"0001826667-25-000014","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus draws $10M from OrbiMed credit facility upon hitting $30M revenue milestone","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$10 million drawdown under $50M credit agreement with OrbiMed triggered by achievement of $30M trailing 12-month product revenue milestone as of Jan 31, 2025.","Total drawn under the facility now $35 million; $15 million remains available.","Proceeds provide additional liquidity for ongoing operations and development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178805,"accession_number":"0001826667-25-000011","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences appoints two new directors, expands board to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Valle (Class I, term to 2027) and Gary Gordon (Class III, term to 2026) appointed Jan 29, 2025.","Valle receives $50k cash retainer plus $7.5k each for Audit and Compensation committees; initial option grant of 35k shares (3-yr vest).","Gordon receives $50k cash retainer plus $7.5k for Science & Technology Committee; same option grant structure as Valle.","No arrangements or understandings existed for selection of Valle or Gordon; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178804,"accession_number":"0001826667-25-000007","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.","Q4 operating cash flow (~$5.6M) improved from (~$10.8M) in Q3.","Expects positive full-year EBITDA in 2025 and positive cash flow during H2 2025.","Cash ~$8.5M; expects to qualify for additional $10M debt tranche from OrbiMed in Q1 2025.","Revenue growth guidance for 2025: in excess of 50%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":29431000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178803,"accession_number":"0001104659-25-002023","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TriSalus promotes James Young to CFO; appoints new CCO and Chief of Clinical Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Young promoted to CFO, effective Jan 6, 2025; annual base salary $420k, target bonus 50%.","Sean Murphy transitions to Chief Manufacturing, Strategy and Business Development Officer; remains on board.","Richard Marshak appointed Chief Commercial Officer; Jodi Devlin appointed Chief of Clinical Operations.","Executive officers elected to forgo $515k in salary for RSUs under new Salary Investment Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195483,"accession_number":"0001104659-24-118338","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.","Operating loss improved to $8.7M (Q3) and $28.6M (9M) from $18.6M and $40.2M in 2023.","Net loss per share $0.12 (Q3) vs $0.14; cash $11.3M plus $25M OrbiMed facility.","2025 guidance: >50% revenue growth, >20% opex reduction, positive full-year EBITDA, H2 cash flow positive.","Launched TriNav LV system and TriGuide catheter; initiated PROTECT trial for thyroid embolization ($400M market)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":21170000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195482,"accession_number":"0001104659-24-113486","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus: Director Anil Singhal resigns; CMO Steven Katz departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Anil Singhal resigned from Board, Compensation and Science/Technology committees effective Oct 28, 2024; no disagreement.","Chief Medical Officer Steven Katz left employment effective Oct 29, 2024.","No replacements announced for either role, creating two leadership vacancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211745,"accession_number":"0001104659-24-089936","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.","Net loss $4.3M ($0.21 per share) vs $14.0M loss a year ago; operating loss $8.2M vs $11.4M.","Closed up to $50M debt facility with OrbiMed; drew $25M at close; cash $16.5M at June 30.","Warrant exchange completed; 79% of public warrants tendered, simplifying capital structure.","Expects final Phase 1 data for nelitolimod in uveal melanoma and pancreatic cancer in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":13821000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211744,"accession_number":"0001104659-24-076841","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences completes warrant exchange, issues 2.1M shares at 0.3 per warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,110,366 shares of common stock in exchange for tendered warrants at a ratio of 0.3 shares per warrant.","Exchange covered public warrants (TLSIW), private placement warrants, and working capital warrants.","Warrant agreement amended with Continental Stock Transfer effective June 26, 2024.","Offer and consent solicitation closed July 1, 2024; Oppenheimer served as dealer manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230490,"accession_number":"0001104659-24-075234","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","3.03","5.07","8.01","9.01"],"status":"ready","headline":"TriSalus completes warrant exchange; 78.9% of public warrants tendered; warrant amendment enacted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,533,614 Public Warrants (78.89%) tendered for 0.30 shares each; settlement by July 1, 2024.","504,685 Private Placement Warrants (10.23%) and 0 Working Capital Warrants tendered.","Warrant Amendment approved for Public Warrants; allows company to force conversion of remaining warrants at 0.27 shares (10% discount).","Registration statement on Form S-4 declared effective by SEC on June 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230489,"accession_number":"0001104659-24-064883","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TriSalus launches warrant exchange offer at 0.3 shares per warrant; seeks to reduce dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering up to 4,264,532 common shares for up to 14.2M warrants (0.30 per warrant).","34.8% of Public Warrants pre-committed; needs ~15.3% more to meet majority threshold.","Consent solicitation seeks amendment allowing forced conversion at 0.27 shares (10% discount).","Expiration date: June 25, 2024; Oppenheimer & Co. is dealer manager.","Company aims to simplify capital structure and reduce future dilutive impact of warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230488,"accession_number":"0001104659-24-061631","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.","Net loss available to common stockholders was $13.2M ($0.60 per share) vs $8.3M loss in Q1 2023.","Closed $25M initial draw on up to $50M debt financing with OrbiMed; expects runway through end of 2024.","Appointed Liselotte Hyveled, Chief Patient Officer at Novo Nordisk, to Board of Directors.","Management reiterates full-year revenue growth guidance exceeding 50%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":6457000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230487,"accession_number":"0001104659-24-057985","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences appoints Liselotte Hyveled to Board, effective May 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to ten directors; Hyveled appointed as Class I director, term expiring at 2024 annual meeting.","Annual cash retainer of $50,000 for Board service; grant of option to purchase 35,000 shares vesting over three years.","Additional $7,500 annual retainer for each of Nominating Committee and Science & Technology Committee membership.","No arrangements or transactions requiring disclosure under Item 404(a); standard indemnity agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230486,"accession_number":"0001104659-24-055007","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences secures up to $50M debt financing from OrbiMed; $25M funded at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M funded on April 30, 2024; up to $25M additional available in two tranches subject to revenue thresholds.","Loan matures April 2029; interest rate is SOFR plus 8.50% (floor 4% SOFR); initial 15 months may accrue up to 3.5% PIK interest.","Issued OrbiMed warrant to purchase 130,805 shares at $9.5562; also registration rights agreement filed.","Company expects cash runway through 2025, targeting break-even EBITDA for TriNav business in 2025.","Covenants require minimum unrestricted cash of $5M (before March 31, 2025) and $10M thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230485,"accession_number":"0001104659-24-047373","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"TriSalus dismisses KPMG, hires Grant Thornton; KPMG cited going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed KPMG as auditor on April 12, 2024; KPMG's reports included a going concern emphasis citing recurring losses.","Engaged Grant Thornton LLP as new independent registered public accounting firm for FY 2024.","No disagreements with KPMG on accounting principles; but material weaknesses in internal controls were disclosed.","Material weaknesses: insufficient trained resources, inadequate controls over business combination, warrant valuation, and equity system conversion.","KPMG's audit reports for 2022 and 2023 contained a separate paragraph on substantial doubt about going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230484,"accession_number":"0001104659-24-041538","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.","Operating loss Q4 $14.1M, full year $54.2M (incl. $7.9M deSPAC costs); net loss $35.5M and $59.0M.","Basic/diluted EPS loss Q4 $1.56, full year $6.73 (vs. $75.01/$161.55 in 2022, impacted by deSPAC).","Will file late 10-K due to stock-based compensation errors; results are unaudited and subject to change.","CMS granted HCPCS code for TriNav; 510k clearance for TriNav Large and TriGuide; phase 1 trials enrollment completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":6457000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248867,"accession_number":"0001104659-24-033157","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).","Gross margin improved to ~90% in Q4 2023 and ~86% for FY2023, vs 75% and 82% a year ago.","Cash and equivalents $11.8M as of Dec 31, 2023; expects liquidity to fund operations into Q2 2024.","Revenue entirely from TriNav Infusion System; final audited financials not yet released.","Preliminary estimates are unaudited and subject to change; auditor has not performed any procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248866,"accession_number":"0001104659-24-006749","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences grants CFO Sean Murphy option for 125,000 shares at $9.28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted on Jan 24, 2024, under the 2023 Equity Incentive Plan.","Exercise price of $9.28 per share, equal to grant-date market price.","Vests 25% on first anniversary, remaining 75% in 36 equal monthly installments.","Contingent on Mr. Murphy's continuous service through each vesting date.","Award recognizes CFO's 2023 performance and aligns long-term incentives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248865,"accession_number":"0001104659-24-001818","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Life Sciences provides slide deck with preliminary 2023 sales, but specific data absent from filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished investor presentation (Exhibit 99.1) covering preliminary 2023 full-year sales and business update.","Presentation available on company website; no financial figures or guidance changes contained in the truncated exhibit text.","No other material developments disclosed; uncertainty precludes extraction of concrete numbers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266404,"accession_number":"0001104659-23-117720","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.","Operating loss $18.5M (incl. $4.8M deSPAC costs); net loss $1.7M; diluted EPS loss $0.13.","PERIO-01 Phase 1 data: median PFS 11.7 months, DCR 81%, 1-year OS 86%.","PERIO-03 initial safety/feasibility for pancreatic cancer; dose expansion with anti-PD-1 expected early 2024.","Appointed Jodi Devlin as President, Commercial Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":12790000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266403,"accession_number":"0001104659-23-106087","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"TriSalus enters $30M standby equity purchase agreement with Yorkville; authorizes up to $4M warrant repurchase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Standby Equity Purchase Agreement to sell up to $30M common stock to Yorkville at 96-97% of VWAP.","Paid $25,000 structuring fee and $300,000 commitment fee; registration statement required before sales.","Board authorized repurchase of publicly-held warrants for up to $4 million.","Advances capped by 4.99% ownership limit and 19.99% exchange cap on outstanding stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283640,"accession_number":"0001104659-23-097730","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences furnishes September 2023 investor slide deck; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide deck posted on company website for investor use; no earnings, guidance, or corporate updates provided.","Presentation reiterates mission to treat liver and pancreatic tumors through immunotherapy and drug delivery technology.","No changes in financial position, operations, or management disclosed; filing is routine Regulation FD disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283639,"accession_number":"0001104659-23-092586","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["1.01","2.01","9.01","3.02","4.01","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"status":"ready","headline":"TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.","Gross proceeds ~$42.9M from trust ($2.7M) and PIPE ($40.15M); ~$9.4M redeemed by MTAC stockholders.","Sponsor earnout shares subject to price milestones ($15-$30) over 5 years; lock-up 365 days or $12 trigger.","FDA acknowledged safety of SD-101 with PEDD but requires additional dose-optimization; NDA submission beyond 2025.","Co plans 40-50 patient study for PERIO-01; Phase 2 initiation targeted in 2023 but subject to change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283638,"accession_number":"0001104659-23-089074","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"MedTech Acquisition shareholders approve TriSalus merger; $9.4M redeemed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All 14 proposals approved by >99% of votes cast at August 8 special meeting.","Holders of 890,499 Class A shares elected redemption for ~$9.42M ($10.58/share) from trust.","Business combination with TriSalus expected to close subject to conditions.","Combined company securities to trade on Nasdaq under symbols TLSI (common) and TLSIW (warrants).","Adjournment proposal not presented due to sufficient votes for all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283637,"accession_number":"0001104659-23-086865","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"MedTech Acquisition adjourns special meeting on TriSalus merger to Aug 8; redemption deadline extended to Aug 4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting for TriSalus business combination adjourned to August 8, 2023 at 11:00 a.m. ET.","Vote to adjourn: 7,134,393 for, 1,777 against; quorum of 96.5% voting power present.","Redemption deadline for public stockholders extended to August 4, 2023 at 5:00 p.m. ET.","Prior to meeting, MTAC filed 8-K regarding FDA written response for TriSalus' PERIO-01 clinical program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283636,"accession_number":"0001104659-23-086578","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA requests additional dose study for TriSalus SD-101; NDA likely beyond 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["TriSalus received FDA written responses on July 31, 2023 for PERIO-01 Type B meeting regarding SD-101 for metastatic uveal melanoma.","FDA acknowledged tolerable safety profile of SD-101 via PEDD with TriNav device, no delivery concerns.","FDA requested additional dose optimization study (40-50 patients) before registrational trial; Phase 2 initiation planned for 2023.","Potential NDA submission for SD-101 in uveal melanoma with liver metastases now expected beyond 2025.","TriSalus also considering separate HCC study with SD-101 plus Y90 radioembolization, prioritization based on H2 2023 data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283635,"accession_number":"0001104659-23-082871","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MedTech Acquisition regains Nasdaq MVLS compliance threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on June 14, 2023 for non-compliance with $35M MVLS requirement.","Nasdaq confirmed MVLS >=$35M for 15 consecutive business days (June 26-July 14, 2023).","On July 17, 2023, Nasdaq notified compliance is regained; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283634,"accession_number":"0001104659-23-078462","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["1.01","1.02","3.02","9.01"],"status":"ready","headline":"MedTech Acquisition raises additional $22.3M in PIPE for TriSalus merger; amends merger agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into subscription agreements for 2,229,500 shares of Series A Preferred at $10/share, aggregate $22,295,000.","Combined with prior $17.855M, total PIPE proceeds of approximately $40.15M.","Backstop Letter Agreement with Sponsor terminated as $2M commitment fulfilled by members via additional subscriptions.","Third Amendment to Merger Agreement updates form of bylaws for post-merger TriSalus Life Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195918746.94720495,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-07-06T23:59:59+00:00|283634"}